Copyright
©2011 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Oct 7, 2011; 17(37): 4153-4156
Published online Oct 7, 2011. doi: 10.3748/wjg.v17.i37.4153
Published online Oct 7, 2011. doi: 10.3748/wjg.v17.i37.4153
Selection criteria for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer
Ingmar Königsrainer, Department of General, Visceral and Transplant Surgery, Tübingen University Hospital, 72076 Tübingen, Germany
Author contributions: Königsrainer I was the sole contributor to this paper.
Correspondence to: Ingmar Königsrainer, MD, Department of General, Visceral and Transplant Surgery, Tübingen University Hospital, Hoppe-Seyler-Str. 3, 72076 Tübingen, Germany. ingmar.koenigsrainer@med.uni-tuebingen.de
Telephone: +49-7071-2985073 Fax: +49-7071-295588
Received: January 24, 2011
Revised: June 9, 2011
Accepted: June 16, 2011
Published online: October 7, 2011
Revised: June 9, 2011
Accepted: June 16, 2011
Published online: October 7, 2011
Abstract
Peritoneal carcinomatosis in gastric cancer is associated with a dismal prognosis. Systemic chemotherapy is not effective because of the existence of a blood-peritoneal barrier. Cytoreductive surgery and intraperitoneal chemotherapy can improve survival and quality of life in selected patients. Patient selection for this multimodal approach is one of the most critical issues, and calls for interdisciplinary evaluation by radiologists, medical and surgical oncologists, and anaesthetists. This article sets forth criteria for selection of gastric cancer patients suffering from peritoneal carcinomatosis.
Keywords: Peritoneal carcinomatosis; Gastric cancer; Hyperthermic intraperitoneal chemotherapy; Cytoreductive surgery; Selection criteria